Friday, May 20, 2022 6:20:19 PM
-- Dr Patterson presented to FDA his research from critical patients in Montefiore , where it shows that the sicker is the patient the higher is CCL5 (Rantes ), and when patients getting better Rantes going down, and in most of this severe/critical patients , Rantes was still very high at 14 days , so why will anyone inject leronlimab only at 0 and 7 day, when at 14 days medicine was still needed.
And Drs , Harish , and Yang and Lalezari presented their experience in treating EINDs patients in covid ..
Nothing else was needed for FDA to approve what company was asking ,
4 doses...but they didn't.
FDA allowed patients with HIV to use leronlimab every week for years , without one serious side effect ..
FDA evaluated studies in HIV for efficacy and safety for 350 , 525 and 700 mg ,
in 24 weeks study so safety can be evaluated , FDA said..., they didn't find any safety problems so they told cydy to use 700 mg in BLA application...,
Now they asked for aggregated safety data so they will have it..but this change nothing..
And they allowed over 100 patients with severe/critical covid to use leronlimab as EINDs, and they were afraid of 2 more doses in our CD12 ?? not possible no matter what the hit letter said..
Why FDA wrote these hit letters I don't know..I really don't know what they want to prove by it , except to damage us in Philippine and India ..imo..
And I also don't know why FDA approved few months ago Biogen drug for Alz..
During study results were terrible.
-- there was no clinical significance .
-- no endpoint met ,
-- no p-value.
Up to 30% patients as a side effects developing cerebral edema and hemorrhage.
And look that at least one patient died already from these side effects after approval..what happen to safety profile here ????
If only anyone will explain how FDA is working , some things we know ,
they catering to BP , BP paying about 50% of their expenses , BP giving them very lucrative jobs when they leaving FDA..
Any other benefits , I don't know , but those are enough already imo.
All IMO.
GLTA longs.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM